Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Neurocrine Biosciences, Inc. (NBIX)

104.94   -1.17 (-1.1%) 08-18 06:34
Open: 106.03 Pre. Close: 106.11
High: 106.47 Low: 104.56
Volume: 499,932 Market Cap: 10,036(M)
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 106.52 - 107.23 107.23 - 107.83
Low: 103.18 - 103.88 103.88 - 104.46
Close: 103.91 - 105.05 105.05 - 105.99

Technical analysis

as of: 2022-08-17 4:25:20 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 127.61     One year: 149.05
Support: Support1: 98.3    Support2: 91.52
Resistance: Resistance1: 109.26    Resistance2: 127.61
Pivot: 100.98
Moving Average: MA(5): 105.79     MA(20): 99.65
MA(100): 94.31     MA(250): 91.42
MACD: MACD(12,26): 3     Signal(9): 2.3
Stochastic oscillator: %K(14,3): 82.4     %D(3): 82.5
RSI: RSI(14): 61.6
52-week: High: 109.26  Low: 71.87
Average Vol(K): 3-Month: 762 (K)  10-Days: 1,058 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NBIX ] has closed below upper band by 33.5%. Bollinger Bands are 105.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Headline News

Thu, 18 Aug 2022
Toronto Dominion Bank Cuts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Wed, 10 Aug 2022
Mizuho Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $98.00 - Defense World

Wed, 10 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) Sets New 12-Month High on Analyst Upgrade - Defense World

Tue, 09 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded to “Strong-Buy” at - Defense World

Sun, 07 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $125.00 at Robert W. Baird - Defense World

Fri, 05 Aug 2022
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 95 (M)
Shares Float 94 (M)
% Held by Insiders 1.3 (%)
% Held by Institutions 99.5 (%)
Shares Short 2,600 (K)
Shares Short P.Month 3,730 (K)

Stock Financials

EPS 4.53
EPS Est Next Qtl -0.41
EPS Est This Year -2.46
EPS Est Next Year -1.71
Book Value (p.s.) 14.19
Profit Margin (%) 5.9
Operating Margin (%) 14.8
Return on Assets (ttm) 5.6
Return on Equity (ttm) 5.5
Qtrly Rev. Growth 31.2
Gross Profit (p.s.) 8.33
Sales Per Share 12.75
EBITDA (p.s.) 2.01
Qtrly Earnings Growth -57.6
Operating Cash Flow 129 (M)
Levered Free Cash Flow 153 (M)

Stock Valuations

PE Ratio 23.11
PEG Ratio -17.9
Price to Book value 7.39
Price to Sales 8.22
Price to Cash Flow 77.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 1995-12-28
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.